Open Access Maced J Med Sci. 2022 Jan 17; 10(B):625-631. 625 Scientifc Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2022 Jan 17; 10(B):625-631. https://doi.org/10.3889/oamjms.2022.7989 eISSN: 1857-9655 Category: B - Clinical Sciences Section: Infective Diseases Promising Indicators in Probiotic-recommendations in COVID-19 and its Accompanying Diseases Vardan Tsaturyan 1,2 , Almagul Kushugulova 3 , Susanna Mirzabekyan 4 , Ketevan Sidamonidze 5 , David Tsereteli 6 , Tamas Torok 7 , Astghik Pepoyan 4 * 1 Department of Military Therapy Yerevan State Medical University, Yerevan, Armenia; 2 International Association for Human and Animals Health Improvement, Yerevan, Armenia; 3 Centre for Life Science, National laboratory Astana, Nazarbayev University, Nur- Sultan, Kazakhstan; 4 Department of Food Safety and Biotechnology, Armenian National Agrarian University, Yerevan, Armenia; 5 Lugar Center for Public Health Research, Tbilisi, Georgia; 6 Department of Communicable Diseases, National Centre for Disease Control and Public Health, Tbilisi, Georgia; 7 Lawrence Berkeley National Laboratory, Berkeley, California, United States Abstract Scientifc data suggests the possible benefcial role of probiotics in treatments for COVID-19, but the species/ strains-specifcity and disease-specifcity of probiotics need high attention in choosing the appropriate probiotic in diseases, in particularly in the COVID-19. We hope this review will raise awareness of the COVID-19 probiotic recommendations, highlighting the latest scientifc information about virus/hydrogen peroxide/probiotics and the importance of fnding out of a specifc “criterion” for the probiotics’ recommendation in this disease. Edited by: Ana Vucurevic Citation: Tsaturyan V, Kushugulova A, Mirzabekyan S, Sidamonidze K, Tsereteli D, Torok T, Pepoyan A. Promising Indicators in Probiotic-recommendations in COVID-19 and its Accompanying Diseases. Open Access Maced J Med Sci. 2022 Jan 17; 10(B):625-631. https://doi.org/10.3889/oamjms.2022.7989 Keywords: COVID-19; Probiotic-specifcity; Oxidative stress; Immunobiotic; Gut microbiota *Correspondence: Dr. Astghik Pepoyan, Department of Food Safety and Biotechnology, Armenian National Agrarian University, Yerevan, Armenia. E-mail: apepoyan@gmail.com Received: 21-Nov-2021 Revised: 30-Dec-2021 Accepted: 07-Jan-2022 Copyright: © 2022 Vardan Tsaturyan, Almagul Kushugulova, Susanna Mirzabekyan, Ketevan Sidamonidze, David Tsereteli, Tamas Torok, Astghik Pepoyan Funding: This research was funded by State Committee of Science of the Republic of Armenia (grant numbers: 10-15/I-5 and 21AG-4D065) and Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (grant number AP09563198). Competing Interests: The authors have declared that no competing interests exist Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution- NonCommercial 4.0 International License (CC BY-NC 4.0) Introduction Literature data indicate an association between COVID-19 severity and diabetes [1], [2]. Most COVID-19 patients are prone to impaired glucose metabolism; glycemic testing and control are important even if the patients have no pre-existing diabetes [3]. Furthermore, hypertension [1], [4], acute coronary syndrome [5], rheumatic [6], gastrointestinal [7], and neurologic features [8], [9] in SARS-CoV-2 infection have been reported. Potential associations between host blood characteristics and gut bacteria [10], [11], [12], as well as between gut microbiota and COVID-19 – accompanying diseases have been actively discussed [13]. Sever childhood respiratory illness in association with vitamin D defciency has also been shown [14]. The clinical trials and experimental studies on COVID-19 treatments are ongoing worldwide, increasing the obtained information on infected people, blood and organ system, genomics, and metabolomics. Despite of a safe and efcacious vaccines, respiratory tract infections will remain of concern for high morbidity and mortality rates among the elderly due to low level vaccine-induced immune response [15], [16]. Recently collected data appear to confrm the possible benefcial role of probiotics in treating COVID-19 patients [17], [18]; however, there is insufcient scientifc evidence specifc to COVID- 19. Therefore, species/strain- and disease-specifcity of probiotics need more attention [19]. Probiotics may have benefcial, harmful, or neutral impact on the host. For example, in an in vivo study of their radio- preventive/protective characteristics, 17 putative probiotic lactobacilli, including the strain Lactobacillus acidophilus DDS ® -1 (from Lacto-G, a marketed symbiotic formulation), the commercial probiotic product Narine (L. acidophilus INMIA 9602 Er-2